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Background: Congestive Heart Failure (CHF) is the most common diagnosis accounting 
for more healthcare costs than any diagnosis. CHF readmissions contribute significantly 
to this expenditure. Quality of care in heart failure is linked to process based performance 
measures. This study evaluated the relationship between adherence to performance 
metrics and 30 day readmission rates. 
Methods: This was a single center case-control study that evaluated 6063 consecutive 
patients admitted with CHF from December 2001 through December 2008. Data was 
collected for readmission to the hospital within 30 days and compliance to the heart 
failure performance measures at discharge. 
Results: The rate of readmission for CHF increased steadily from 16.8% in 2002 to 
24.8% in 2008. Adherence to CHF performance measures increased concurrently during 
the same time frame from 88.7% to 98.9%.Except for left ventricular function (LVF) 
assessment, 30 day readmission rate was not associated with adherence to performance 
measures. Readmitted patients had twice the odds of not having their LVF assessed (OR: 
2.0; p<0.00005; 95% CI: 1.45-2.63) 
Conclusions: Heart failure performance measures, except for the assessment of left 
ventricular function have little relationship with 30 day hospital readmissions after 
discharge. More studies need to be done to identify performance measures that correlate 







Congestive heart failure (CHF) is a very common and disabling health problem
seen most commonly in patients above 65 years (AHA, 2005; Kannel & Belanger, 1991). 
The incidence of CHF increases with age. CHF is a syndrome in which the heart is not 
able to meet the body’s metabolic demands thus resulting in a variety of symptoms where 
the body suffers from effects of inadequate oxygen. This leads to symptoms such as 
shortness of breath, fatigue, poor exercise tolerance and fluid retention in various tissues 
of the body. CHF is a major public health problem in the western world. In the US alone 
there are about 5 million Americans living with the diagnosis of heart failure. It is also
estimated that another 550,000 Americans are diagnosed with this condition every 
year(AHA, 2005). CHF accounts for about 15 million physician office visits every year 
(O'Connell & Bristow, 1994). CHF is the most common Medicare discharge diagnosis 
accounting for more healthcare costs than any other condition in the US (Massie & Shah, 
1997). The overall prevalence of heart failure is increasing as the segment of the elderly 
population increases. Hospitalizations with a primary diagnosis of CHF among adults 
(age ≥35) increased from 810,624 in 1990 to 989,500 in 1995 and to 1,088,349 in 1999 
(Koelling, Chen, Lubwama, L'Italien, & Eagle, 2004). 
This increase has been attributed to the aging population and the advances in the 
treatment of coronary artery disease (CAD) that have led to more people surviving initial 
events of acute myocardial infarction (Senni et al., 1999). CHF is primarily a disease of 
the elderly as evidenced by the fact that 80% of the patients admitted with heart failure
are over the age of 65 years (Masoudi, Havranek, & Krumholz, 2002). The incidence of 




Belanger, 1991). Congestive heart failure is very prevalent and the magnitude of the 
problem is such that, it is associated with high healthcare expenditure estimated to be 
about over $35 billion per year in the USA (Massie & Shah, 1997; O'Connell & Bristow, 
1994). Most of the expenditure is due to frequent readmissions of patients with this 
condition. Twenty percent of all patients discharged from the hospital with heart CHF are 
readmitted within the first 30 days and 50 % within 6 months (Masoudi et al., 2002; 
Senni et al., 1999). 
Risk Factors 
There are many factors that predispose to heart failure. Hypertension is the 
commonest risk factor for heart failure followed by antecedent acute myocardial 
infarction (AMI) (Levy, Larson, Vasan, Kannel, & Ho, 1996). The other risk factors 
include diabetes, metabolic syndrome, dilated cardiomyopathy, smoking and excessive 
alcohol use. Diabetes mellitus increases substantially the risk of developing CHF 
especially among post menopausal women with established coronary artery disease. CHF 
incidence increases with each additional risk factor, for example, the annual incidence of 
CHF among non diabetic women with no risk factors was 0.4%. This risk increased to 
3.4% in the non diabetic women with at least 3 traditional cardiovascular risk factors. 
Examples of traditional risk factors include diabetes, smoking, hyperlipidemia, and 
hypertension. Among diabetic persons with no additional risk factors, the annual 
incidence of CHF was 3.0%, compared with 8.2% among diabetics with at least 3 
additional risk factors (Bibbins-Domingo et al., 2004). 
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Classification of Heart Failure 
There are numerous ways of classifying heart failure and in many cases these 
categories overlap and maybe ambiguous. The basis of these definitions have varied 
widely and have ranged from, anatomical (right versus left sided heart failure), 
physiological (diastolic versus systolic), and in some instances clinical considerations 
(acute versus chronic). The World Health Organization (WHO) classification is based on 
the nature of myocardial disorder (i.e. dilated, hypertrophic, restrictive, arrhythmogenic 
right ventricular and unspecified cardiomyopathies) (Richardson et al., 1996). 
In recognition of the fact that heart failure is a progressive disorder, the American 
Heart Association (AHA) and the American College of Cardiology (ACC) Societies have 
developed in collaboration the staging criteria that takes into account the development 
and progression of the disease (Hunt et al., 2001). This classification has 4 stages; A 
through D. 
Stage A identifies patients that are at high risk for developing heart failure but 
have no structural abnormalities of the heart and have no symptoms of heart failure. 
These are patients that might have risk factors for developing heart failure such as 
hypertension, diabetes, and coronary artery disease, history of alcohol abuse or exposure 
to cardio toxins. 
Stage B includes patients with structural heart abnormalities but with no overt 
symptoms of heart failure. Patients in this stage might have left ventricular hypertrophy 
(LVH), reduced left ventricular ejection fraction (LVEF), valvular disease and prior 





Stage C includes patients that have all the factors in stages A and B, and in 
addition have symptoms of clinical heart failure. They have not only structural 
abnormality of the heart but manifests clinical symptoms and signs of clinical heart 
failure.
Stage D includes patients that are refractory to standard treatment of heart failure. 
These are patients that may require intravenous medications, on an outpatient basis, that 
help stimulate the contraction of the heart. The other modalities of treatment for this stage 
include mechanical assist devices, heart transplant or hospice care.  
In the ACC/AHA staging of heart failure, a classification that takes into account 
the severity and progression of heart failure, patients can progress from one lower stage 
to a higher stage but never the reverse, i.e. from stage A to B and never from B to A. 
There is another more clinically based classification or staging of heart failure called the 
New York Heart Association (NYHA) classification. This classification of heart failure 
uses the presence or absence of symptoms of heart failure on functional capacity to 
classify severity of heart failure (Gibelin, 2001). There are 4 classes in this classification I 
through IV. 
Class I No Limitation of physical activity. Ordinary physical activity does 
not cause undue fatigue or dyspnea 
Class II Slight limitation of physical activity. Comfortable at rest, but 
ordinary physical activity results in fatigue or dyspnea. 
Class III Marked limitation of physical activity. Comfortable at rest, but less 




Class IV	 Unable to carry on any physical activity without discomfort. 
symptoms at rest.  
Path Pathophysiology of Heart Failure 
There have been numerous conceptual models that have been proposed to explain 
heart failure; however, no one single model effectively explains the complexity of the 
heart failure syndrome. Earlier models conceived heart failure as a result of excessive salt 
and water retention leading to poor renal flow (cardio renal model) (Packer, 1992). 
Following this, there was the hemodynamic model which conceived heart failure as a 
problem of “pump failure” with resultant excessive peripheral vasoconstriction (Mann & 
Bristow, 2005). These models could not, however explain the progression of heart failure 
once the original insult causing heart failure was removed. More recently, the “neuro 
hormonal model” has attempted to explain the progression of heart failure as resulting 
from the effects of biochemical molecules released in response to injury of the heart 
(Bristow, 1984). These biomedical chemicals include catecholamine’s, through the 
activation of the adrenergic nervous system (ANS); angiotensin II and aldosterone 
through the activation of the rennin-angiotensin-aldosterone system (RAAS). With a 
reduction in the cardiac output resulting from an insult on the heart (index event), 
compensatory mechanisms are set in motion with the goal of maintaining adequate 
cardiac output for tissue perfusion. An activated autonomic nervous system and rennin­
angiotensin -aldosterone system results in the over expression of catecholamine’s, (also 
known as the “flight hormones”), angiotensin II and aldosterone respectively. These 
biochemical molecules have profound maladaptive effects on myocardial cells (Bristow, 







cardiac muscle (also known as remodeling). The overall result is that the heart 
configuration changes from the elliptical shape to a more spherical shape which is less
efficient in pumping out blood. Patients may be asymptomatic after the index event but 
with persistence of these maladaptive changes, patients develop overt symptoms of heart 
failure. Therapeutic agents such as beta blockers (BB) and angiotensin converting 
enzyme inhibitors (ACEI) have been shown to improve survival in heart failure by 
ameliorating the effects these maladaptive changes directly through  the ANS and RAAS 
respectively(Currie et al., 1984; Fox et al., 2001; Ikram & Fitzpatrick, 1981). This 
conceptual frame work helps to explain the changes in the development of systolic 
dysfunction (heart failure with depressed ejection fraction, less than 45%). However, the 
maladaptive changes in diastolic dysfunction (heart failure with preserved ejection 
fraction) are not very well understood. 
LITERATURE REVIEW: 

Review of Evidence for Medical Treatment of CHF 

The treatment for heart failure is divided in to acute phase and maintenance phase. 
In the acute phase, the main goals are resuscitative, symptom relief and restoration of the 
normal physiology. The maintenance phase (or implementation phase) involves the 
administration of life saving treatments that have been shown to improve outcomes in 
patients with heart failure. There are some medications that have been shown to reduce 
mortality of heart failure patients and these include, angiotensin converting enzyme
inhibitors (ACEI), and beta blockers (BB).Other medications that have scientifically 
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ACE inhibitors 
ACEI are a group of medications that inhibit the conversion of angiotensin I to 
angiotensin II. Angiotensin II has been implicated in long-term deleterious effects on the 
heart and hence suppression of this enzyme has important clinical implications in patients 
with heart failure.
The use of ACEI is recommended for most patients with stage B, C, D. These 
classes of medications have been shown to confer survival benefit to patients with heart 
failure, after myocardial infarction, improve heart failure symptoms and reverse 
remodeling by blunting the activity of the RAAS (Garg & Yusuf, 1995; Khalil, Basher, 
Brown, & Alhaddad, 2001; Munzel & Keaney, 2001). The effects of these medications 
are not dose dependent. The effects of low dose ACEI on mortality has not been any 
different than in those patients taking high dose regimens in most randomized clinical 
trials (Packer, 1992; Tang et al., 2002). 
Beta Blockers (BB) 
The other class of medications that has been shown to be beneficial in patients 
with heart failure are beta blockers. Beta blockers have been shown to confer clinical 
benefits in patients with all stages of heart failure. The benefits that beta blockers confer 
include survival, morbidity, and quality of life, rate of hospitalizations, remodeling and 
incidence of sudden cardiac death (Farrell, Foody, & Krumholz, 2002; Foody, Farrell, & 
Krumholz, 2002). Studies have shown improvements in the systolic function and reversal 
of remodeling with just 3 to 4 months of treatment with beta blockers (Bristow, 2000; 




and hospitalization were seen as early as 14 to 21 days after initiation of therapy (Krum et 
al., 2003). 
Beta blockers are medications that reduce the effect of sympathetic activity on the 
heart and blood vessels by blocking the action of these “flight hormones” on the heart 
and blood vessels. An overactive sympathetic activity has been shown to lead to 
deleterious effects on the heart. Blunting the effect of these catecholamine’s in patients 
with heart failure leads to improved outcomes in both morbidity and mortality rates. 
Angiotensin receptor blockers (ARBS) 
Angiotensin receptor blockers block the actions of the enzyme angiotensin II at 
the angiotensin II type 1 receptor site. Angiotensin receptor blocker are comparable, but 
not superior to angiotensin converting enzyme inhibitors (Cohn & Tognoni, 2001; 
McMurray, Pfeffer, Swedberg, & Dzau, 2004; Pitt et al., 2000). There are reports of 
increased adverse events in patients who were receiving combination of both these 
medications rather than one or the other (Baruch et al., 1999; McMurray et al., 2003). 
Angiotensin receptor blockers are therefore generally recommended in patients who are 
not able to tolerate angiostensin converting enzymes inhibitors,  such as cough 
angioedema. 
Aldosterone antagonist 
Aldostereone antagonists are another class of medications that have a beneficial 
role in heart failure (McMurray & O'Meara, 2004). Patients with heart failure have 
elevated levels of the hormone aldosterone which leads to salt and water retention. Salt 
and water retention contribute to worsening of heart failure. Aldosterone also works 





antagonist counteracts these effects thereby inhibiting the remodeling process (Weber, 
2001). Randomized controlled studies have shown that  adding these agents to the drug 
regimen of patients with advanced heart failure (New York heart classification  class III 
or IV) improves mortality outcomes and hospital admissions for heart failure (Pitt et al., 
1999). 
Causes of heart failure 
The most common cause of heart failure in the western world is attributed to 
coronary artery disease and may often be secondary to an acute myocardial infarction. 
Coronary artery disease accounts for about 70% of the cases of heart failure (Fox et al., 
2001). Heart failure can also result from non ischemic causes such as hypertension, 
cardiomyopathies, heart valvular disorders, pericardial disorders or arrhythmias.  
Review of evidence on CHF readmissions
Readmissions to the hospital for heart failure may be influenced by multitudinous 
factors such as the severity and stage of the illness, preexisting co-morbid conditions,
compliance to prescribed medications, and diet. Other predictors of early readmission to 
the hospital include uncoordinated discharge medications, such that the patient may not 
be taking the newly adjusted dosages of heart failure medications initiated in the hospital 
and may in fact resume the preadmission medications which may have been inadequate 
to treat the heart failure condition to begin with. This is otherwise known as post hospital 
discharge medications discrepancy (Coleman, Smith, Raha, & Min, 2005). Unco­
ordinated discharge plans between hospital physician and primary care physicians in the 
communities have been associated with the increased hospital readmission. Rich and 




heart failure by as much as 28 percent (Rich et al., 1995). Another study by Philips and 
colleagues showed that post discharge support in elderly patients showed favorable 
outcomes and reduced readmissions (Phillips et al., 2004) . 
Demographic predictors 
Race can be a relevant predictor of hospital readmissions. Studies have shown 
that Blacks in general do not seek healthcare early and are more prone to readmissions 
than their White counterparts (Evangelista, Dracup, & Doering, 2002; Rathore et al., 
2003). The impact of gender on readmissions is unclear because some studies suggest 
that males are more likely  to be readmitted than females (Sueta, Schenck, Chowdhury, 
Hall, & Simpson, 2000), while other studies  suggest that females have higher rates of 
readmission  Alonso Martinez, Llorente Diez, Echegaray Agara, Urbieta Echezarreta, & 
Gonzalez Arencibia, 2001). Independent of sex and gender, hospital readmissions  
increase with age greater than 65 years of age (Kossovsky et al., 2000; Krumholz et al., 
2000). 
Compliance to medications in the outpatient setting may also be related to quality 
of discharge planning. 
Co-morbid conditions
The associated co-morbid conditions are also associated with readmission rates of 
heart failure. Conditions such as chronic kidney disease, pulmonary disease, 
hypertension and diabetes can predispose patients to readmissions (Tsuchihashi et al., 
2001). A study by Brausntsein and colleagues (2003) found that about 40 % of patients 
with heart failure have at least 5 non cardiac co-morbidities and these account for about 








Certain clinical variables are associated with increased hospitalizations. Some of 
these variables include, low cardiac functional status or reserve. The lower the ejection
fraction or cardiac reserve, the higher the severity of heart failure and higher the 
likelihood of readmissions. Another clinical variable that may impact readmissions is the 
NYHA classification of heart failure. Higher stages of the NYHA imply advanced 
disease and therefore will lead to increased length of stay of patients in the hospital 
(Philbin & Roerden, 1997). 
Medications
Studies are conflicted on the impact of CHF medications on hospital 
readmissions. ACEI use have been shown to reduce readmissions (Holst et al., 2001). On 
the other hand, the impact of beta blockers is mixed, with some studies suggesting that, 
beta blockers reduce hospital readmissions while other studies suggest that, they do not 
impact the rates of readmissions (Cobelli, 2000; McDonald et al., 2001). 
Process of care 
There is evidence to suggest that the process of care of patients with CHF can 
affect their outcomes. Some studies have shown that  involvement of the cardiologist in 
the care of patients while they are in the hospital reduces the length of stay in the hospital 
and subsequent rates of readmission (Cobelli, 2000; McDonald et al., 2001; Polanczyk, 
Newton, Dec, & Di Salvo, 2001). There is also data to show that the quality of outpatient 
management of heart failure affects the rates of readmissions (Kossovsky et al., 2000). A 
multidisciplinary  approach to the management of patients with heart failure has been 








1999). This is in keeping with the complexities of variables that may affect heart failure 
readmissions. Variables that reduce readmissions may range from timely follow up visits 
with the primary care physicians and early symptom recognition (Evangelista, Dracup, & 
Doering, 2000). Rich and colleagues (1995) reported in their study that a nurse directed 
multidisciplinary intervention, involving diet education; prescription medications and 
follow-up coordination resulted in reduced readmissions and lower cost of care in 
patients with heart failure. The interventions were much more effective in the elderly
patients.
McDonald and colleagues (2002) also validated these results indicating that 
patients receiving a multidisciplinary intervention had better outcomes in terms of 
readmissions and death compared to the group that had optimized medical care only.
Psychosocial factors
Patients’ psychosocial conditions can also affect the readmissions to the hospital. 
Low social economic class, single marital status and depression  have been associated 
with increased rates of readmissions (Philbin, Dec, Jenkins, & DiSalvo, 2001). Vansuch 
and colleagues reported that discharge instructions to patients with heart failure as well as 
patient education does reduce the number of readmissions and mortality due to CHF 
(VanSuch, Naessens, Stroebel, Huddleston, & Williams, 2006). 
National Quality Measures 
Healthcare organizations are required to collect information on the delivery of 
healthcare services to evaluate the quality of their services as well as report outcomes to 
third party payers as well as to credentialing organizations. The two most important 




(CMS) and the Joint Commission on Accreditation of Healthcare organizations (JCAHO) 
also known as the Joint Commission. CMS is a federal government program which serves 
as a payer for healthcare services rendered on behalf of its Medicare and Medicaid 
patients. The Joint Commission on the other hand is a private sector, not for profit 
organization that credentials hospitals and healthcare organization in the US. 
Accreditation by the Joint Commission is a requirement if the healthcare 
organization is to get reimbursement for services rendered on behalf of Medicare and 
Medicaid patients. Hospitals accredited by the Joint Commission are required to assess 
quality using prescribed measures called core measures for specific diseases. Heart 
failure is one of the diseases the hospital can choose to assess. These measures are based 
on peer reviewed studies which provide evidence of the association of the measure with 
clinical outcomes. Some of the measures are based on expert consensus opinion. For 
heart failure, the core measures are: Assessment of left ventricular function (LVF), 
Prescription of ACEI to patients with low, provision of adult smoking cessation advice 
for patients that smoke. The other measure is based on expert consensus opinion and is 
based on documentation that patients received discharge instructions or educational 
materials on six metrics which include: activity, weight, diet, and discharge medications, 
follow up appointments and worsening of symptoms (Hunt et al., 2001). 
CMS in the early 1990s transitioned from merely acting as a payer of services for 
its clients to an insurer also focused on quality of care. This led to a series of quality 
initiatives aimed at improving the quality of healthcare that its beneficiaries were 
receiving. In 2003 the Center for Medicare Service (CMS) initiated a program called 




quality of care services in the hospitals. In this program, hospitals adhering to evidence 
based practices are rewarded with increased payments on Medicare patients. Participating 
hospitals have CHF discharge teams or planners to assure adherence with evidence based 
guidelines in heart failure prior to discharge from the hospital. Thus hospitals are 
expected to monitor and report to CMS the number of patients discharged on ACEI, left 
ventricular function assessment, smoking cessation counseling, and discharge instructions 
on for heart failure. These variables constitute the “core measures” on patients discharge 
from the hospital with heart failure.  
Early readmission of heart failure has been linked to quality of care, with 
suggestion that patients being readmitted have poor quality of care (Ashton, Kuykendall, 
Johnson, Wray, & Wu, 1995). Other studies have not shown such a link between early 
hospital readmissions and quality of care for patients with heart failure (Kossovsky et al., 
2000). The CMS however, does not reimburse hospitals for the care of patients who are 
readmitted within a period of 30 days. The reimbursement is bundled up with the prior 
hospitalization. It is imperative therefore for hospitals to prevent early readmissions for 
heart failure. Most hospitals track patients with heart failure that are readmitted within 
this 30 days period for administrative purposes. It is important for hospitals to keep such 
administrative records for planning purposes to minimize non-reimbursable care. 
OBJECTIVES: 
The aim of this study is to: 
1. Investigate the rates of adherence to the heart failure performance measures in 






2. Study the relationship between hospital adherence to heart failure performance 
measures and rates of 30 day readmissions in patients discharged from the hospital with 
heart failure.
Study Research Question: The primary research question of this study is: Does 
adherence to heart failure performance measure at discharge from the hospital translate to 
reduced 30 day readmissions? 
STUDY DESIGN: 
Methods 
This is a retrospective descriptive study designed to compare the rates of early 
readmission among patients with heart failure before and after the implementation of 
discharge planning strategies in 2005 at the Kettering Medical Center in Ohio. Early 
readmission is defined as readmission to the hospital within 30 days of discharge from
the hospital. Subjects include all the patients with CHF who were readmitted at the 
hospital between years 2001-2008. Readmission is defined as admission to the hospital 
within 30 days of discharge from the hospital.  
All patients admitted to the hospital between December 2001 and December 2008 
were reviewed. There were total 6,065 patients admitted with the diagnosis of heart 
failure. These patients were identified from the heart failure registry using the diagnostic 
related group (DRG) codes ascribed for heart failure. From this composite, data of 
patients that were admitted for heart failure, and data from patients who had presented to 
the hospital within 30 days of discharge were discriminated by the unique medical record 







Data were extracted from the electronic medical records for patients who had met 
readmission eligibility. Data collected included demographic information, co morbid 
conditions, diagnostic tests, pre-admission and post discharge medications and adherence 
to heart failure core measures at discharge. Both the Kettering Medical Center and the 
Wright State University’s Institutional Review Boards reviewed and approved this study. 
Statistical Analysis 
Categorical variables are expressed as numbers and percentages while continuous 
variables are expressed as means. The chi-square test was used to measure association 
between variables, and to describe the relationship between the heart failure performance 
variables and the dependent variable (readmission rate). Statistical significance was set at 
p<0.05. Crude rate of readmissions were calculated by dividing the number of 30 day 
readmissions by the total number of heart failure admissions during the specified time 
interval. Data was imported into Excel worksheet for descriptive statistical analysis of
categorical variables. Chi-square test using the Epi Info® program was used to identify 
associations between independent and dependent variables.  
RESULTS:
There were 6,063 patients admitted for heart failure between December 2001 and 
December 2008. During this time 19.6% (1,191) of the patients were re admitted to the 
hospital within 30 days of discharge (see Figure 1) .The baseline characteristics of the
study group are as shown Table 1. The average age of patients was 77.4 (SD 11.2). 
55.6% of the patients were female.  
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Table1. Patient Characteristics 
Female 52.6% 
Male 47.4% 





Diabetes 73.8 % 
Smokers 62.3% 
The patients admitted for heart failure were more likely to have other co-morbid 
conditions reflecting the fact that CHF is disease of the elderly with multiple risk factors. 
Two-thirds (76.4%) of the study population had hypertension, while 74.0% had coronary 
artery disease. Another 74.0% of the study population had history of cerebrovascular 
accidents (CVA). Patients with a history of peripheral vascular disease comprised 70.3% 
of the study. Patients with a history of diabetes comprised 73.8% of all patients admitted 
with heart failure.
Readmissions 
The number of readmissions for heart failure steadily increased over the years. In 
2002 the 30 day readmission rate was 16.8% while in 2003 through 2008; the rate of 
readmissions was 19.0%, 17.6%, 18.4%, 21.4% and 24.8% respectively (Table 2). The 
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maximum stay of 59 days. During the time of the study, the adherence rate for all the four 
heart failure core measures increased steadily from 88.8% to 98.9%.The rate of 30 day 
readmissions for heart failure during the same time increased from 16.8% to 24.8%.  
Figure 1 



























Readmission All 4 performance measure compliance 
Graph of the temporal trends of compliance to all the four performance measures in 
relation the rates of CHF readmission during the study period. 
Performance Measures
Adherence to heart failure performance measures had improved overtime from
16.8% in 2002 to 24.8% through 2008. This improvement in adherence to the 
performance measures over the six year period may be due to a change in government 
policy in 2005 resulting in the CMS offering incentives of higher payments to health care 
providers adhering to performance measures linked to quality of care. Hospitals are rated 













therefore imperative for hospitals to find ways and means to adhere to these performance 
measures in order increase revenue on one hand and to improve their public image as 
centers of excellence, on the other hand. Although the general trend was overall 
improvement in all the performance measures over time, the smoking cessation core 
measure had the greatest increase with 97.8% adherence, while ACEI use core measure 
had a 96% adherence rate. The adherence rate for the left ventricular assessment core 
measure was 94%. However, the core measure of discharge instruction (at time of
discharge) ranked the lowest at 77.6% over the six years of the study. 






















2008 713 177(24.8) 8 1 0 0 
2007 859 184(21.4) 23 0 4 0 
2006 866 177(20.3) 19 2 3 1 
2005 894 165(18.4) 11 6 8 0 
2004 1007 178(17.6) 26 14 11 4 
2003 886 169(19.0) 86 23 14 
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Graph of the temporal trends of compliance to all the performance measures in the study
times frame       
Figure 3 

Non Compliance and Readmissions 









f non adhere 
2003 20 





s and CHF 














Table 3. Statistical Correlations between Adherence to Performance Measures and 
Readmissions 
Performance Variable Odds Ratio 95% CI P value 
Left Ventricular Assessment 1.02 1.45-2.63 0.000005 
Smoking Cessation 1.03 0.65-1.62 0.89 
ACEI usage 1.3 0.98-1.96 0.06 
Discharge Instructions 1.02 0.88-1.20 0.76 
Heart failure discharge instructions and readmission 
Two hundred and sixty-seven (22.3%) of the 1,191 patients readmitted for heart 
failure between 2002 and 2008 presented lack of compliance to discharge instructions. 
Those patients not readmitted within 30 days (for heart failure) had 22.1% (1071) lack of 
compliance to discharge instructions.
There was no significant association between readmission rates and not giving 
discharge instructions (OR= 1.02, 95%CI= 0.88-1.20, p= 0.76). 
Correlation of smoking cessation and readmission 
Among patients readmitted with heart failure during the study period, there were 
2.2% (26) who had not received smoking cessation instructions before hospital discharge. 
On the other hand, of the 4,865 patients who were not readmitted for heart failure, there 
were 2.1% (103) patients who were not given discharge instructions. 
There was no association between not receiving a smoking cessation plan at 





Correlation of ACEI and readmission 
In the group of patients who were readmitted for heart failure, 4% (48) did not 
receive ACEI therapy, while in the group of patients that were not readmitted within 30 
days, 3% (143) did not receive the medications.
Despite a trend towards reduction in the 30 day readmissions associated with 
ACEI therapy, there was however no statistical significance in the findings (OR= 1.3, 
95% CI 0.98-1.96, p=0.06). 
Correlation of LV assessment and readmission 
Out of the 1,191 patients readmitted with heart failure, 6% (72) did not have their 
left ventricles assessed prior to discharge from the hospital by their physicians. In the 
group that was not readmitted, 3.1% (155) did not have left ventricular assessment. There 
was a significant relationship between ventricular assessment and readmission (O.R=2, 
95% CI 1.45-2.63, p=0.000005). 
DISCUSSION: 
Readmission to the hospital is influenced by a multitude of factors. Some factors 
can be related to social-economic factors. Philbin and colleagues (2001) reported low 
social economic status is related to increased readmissions. Patient compliance to 
treatment outlined by healthcare providers can also influence the rate of rehospitali­
zations (Tsuchihashi et al., 2001). Presence or absence of co-morbid conditions such as 
renal failure, chronic obstructive pulmonary diseases may have an effect on the heart 
failure readmission rates. Komukai and colleagues (2008) found that preexisting 
conditions such as renal failure were associated with increase readmissions to the 
hospital. These findings were also confirmed by Burns who reported that multiple past
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hospitalizations secondary to other medical conditions were associated with readmission 
to the hospital with CHF (Burns & Nichols, 1991). Anemia in patients with heart failure 
was found to be a predictor of early readmission to the hospital and death (Felker et al., 
2003). 
Readmissions can also be related to process of care, for instance, when the patient 
is not started on evidence based therapies for heart failure. Ashton and colleagues found 
that readmissions to the hospital may be an indicator of poor quality care in patients 
being treated for heart failure. They reported that patients discharged early from the 
hospital prior to complete resolution of symptoms were more likely to be readmitted 
within 14 days from discharge (Ashton et al., 1995). Whellan and colleagues (2001) have 
proposed that case management in patients with heart failure improves the quality of care 
and outcomes. These disease management programs help guide management of patients 
with chronic medical conditions by offering a system of coordinated healthcare 
interventions. 
The CMS links quality of care to 4 performance core measures for heart failure. 
These measures include discharge instructions, left ventricular assessment, smoking 
cessation counseling and administration of ACEI. In our study, these core measures had 
no association with the rate of readmissions to the hospital within 30 days of discharge 
from the hospital. The independent relationship of heart failure performance measures 
and readmission rate can be attributed to the heterogeneity of the factors influencing 
readmissions to the hospital.  
Philbin and colleagues (2001) did not find any relationship between early 






failure patients. In the same study, they reported an association between patient’s clinical 
and demographic characteristics with readmissions to the hospital. Patients of lower 
social economic class were more likely to be readmitted for heart failure (Philbin et al.,
2001). Even though this study did not show a correlation between adherence to heart 
failure performance measures and readmissions, there are some studies that have shown 
the contrary. For instance, Chung and colleagues (2008) showed that adherence to heart 
failure performance measures reduced all cause heart failure readmissions to the hospital, 
although in their study, the sample size was small and the duration of follow up was only 
6 months. Even though, Chung’s study showed positive correlation of adherence to the 
core measures with readmissions, this did not show any significant association between 
the adherence to heart failure performance measures and the 30 day hospital readmission 
rates. Some authors have argued that what may be more important is whether patients are 
being discharged on the optimal dosages of ACEI, instead of merely documenting that 
patients was discharged on an ACEI (McDonald et al., 2001). In his study, he found that 
patients who were discharged on the target dosages of ACEI had less readmission rate 
within 30 days. In another study by VanSuch and colleagues (2006), adherence to 
discharge instructions was associated with reduced readmissions for heart failure. 
The lack of effect of the four performance measures (discharge instructions, left 
ventricular assessment, smoking cessation counseling and administration of ACEI) on 30 
day readmissions may relate to the fact that readmissions for heart failure are influenced 
by a heterogeneous group of factors. Two of the four measures, use of ACEI and 
smoking cessation take a much longer period of time to demonstrate benefit. For 





process to eventual abstinence may be marked with episodes of recidivism and take years 
to attain. Even in the event that the patient has quit smoking, the clinical benefits of 
smoking cessation may take much longer than 30 days to realize. ACEI on the other hand 
inhibits the hormone angiotensin converting enzyme that has been implicated in the 
pathogenesis of heart failure. Inhibition of this enzyme may take weeks before clinical 
benefits are seen. 
Assessment of left ventricular function may have implications on disease severity 
and guide therapy in heart failure. However merely assessing and documenting that 
ventricular function was performed during hospitalization does not imply that therapy for 
heart failure was optimized. In one study by Luzier et al. (1998), they reported that most 
patients discharged with ACEI medications were not on appropriate dosages. In fact, they 
reported that heart failure readmissions reduced by up to 28% in patients with ACEI 
dosages about 8-10 times higher than the commonly used dosage regimens (Luzier et al., 
1998). 
Limitations
There a few limitations of this study that are worthy of mention. One overarching 
limitation is that this is a retrospective study and hence, the myriad etiological factors 
responsible for readmissions in heart failure patients could not be controlled for. For 
instance, infection is a common cause of heart failure exacerbations which can directly
affect readmission. This study did not investigate the reasons for the exacerbation of heart 
failure necessitating readmissions to the hospital. Poor compliance to medications is 
another reason for recidivism. These and many other specific reasons for heart failure 






impression that heart failure readmission rates are only related to the heart failure 
performance measures that we have been studying. There are also patient attributable 
factors such as demographic variables, social economic status, coexisting medical 
conditions and other psychosocial factors that may influence the rates of readmissions in 
heart failure. Provider specific variables such as experience of the attending physician 
and whether a cardiologist was involved (or not) in the care of the patient are also 
important. These variables can influence the quality of care provided to heart failure 
patients and by extension the rates of readmissions. This study did not take into account 
the impact of any of these variables on readmissions. This study used existing 
administrative data to make inferences on the relationship between performance measures 
and readmissions. In one study by Hallerbach and colleagues (2008), they found that in as 
many as 50% of all the patients readmitted had been labeled incorrectly, raising serious 
questions about using administrative data alone to determine quality of care.
Another limitation of this study is that it was a single center study in a community 
hospital serving a predominantly elderly, affluent community. The findings may reflect 
the inherent biases of the institution and of its clientele, in which the study was 
conducted. 
Public Health Policy Implications
This study is expected to shed more light and help us understand the factors 
influencing readmissions rates to the hospital in patients with CHF. This knowledge is 
important clinically in that it, it would shape clinical care practices that if properly 




There is the perennial debate about the high spiraling cost of healthcare in the US 
and a quest for the most effective ways of reducing these healthcare costs while at the 
same time ensuring that quality of healthcare is enhanced. Heart failure is the most 
common diagnosis with significant contribution to healthcare costs. Finding ways that 
improve quality of health and at the same time reduce the cost of care is extremely 
important. Heart failure readmissions increase significantly the burden of healthcare 
costs. From the public health standpoint, reducing the incidence and prevalence of heart 
failure is the ultimate goal. This might be done through risk factor reduction and effective 
public health education. However the intermediate goal would be to improve the quality 
of life of patients with heart failure both by using evidence based practices and by 
improving the process of care that enhances the lives of heart failure patients. Admission 
of patients to the hospital is not only an opportunity for clinicians and healthcare 
providers to address patients immediate health concerns (that prompted them to seek help 
in the first place), but it is also an opportunity for healthcare providers to coordinate 
healthcare resources, and to promote educational interventions proven to improve the 
quality of lives of patients. 
CONCLUSIONS:  
This study showed that there was no significant association between hospital’s 
adherence to the heart failure performance measures and 30 day readmission rate. There 
was a statistically significant relationship between the lack of left ventricular assessment 
and readmission rate. There was also a trend towards reduced readmissions in patients 
with ACEI although the results were not statistically significant. Left ventricular function 




low ejection fraction may be initiated on evidence based therapies known to improve 
outcomes. Patients with low ejection fraction (cardiac reserve) are candidates for 
angiotensin converting enzyme inhibitors, medications that have been shown to have 
improved outcomes in heart failure patients. Therefore left ventricular function 
assessment may be a surrogate indicator of quality of care in heart failure patients. More 
studies should be done to address the relationship between the current heart failure 
performance measures and how they relate to quality and outcomes of care in heart 
failure patients. Studies should also address current performance measures and whether 
they should continue to be used as surrogate indicators for the quality of care and how 
these measures impact clinical outcomes. In lieu of the findings of this study, policy 
makers should delineate measures that could be labeled as "good practices" for health 
care providers from the "core measures". "Good practices" could include among others, 
measures such as smoking cessation counseling and discharge instructions given to 
patients prior to discharge. These measures while important in guiding healthy behavior 
choices in heart failure patients still remain unsubstantiated in terms of hard scientific 
evidence in influencing outcomes. Furthermore, these measures are not only variable in 
how they are implemented by health care providers but how they may be adopted by 
patients. On the other hand, "core measures" should be substantiated to improve 
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APPENDIX 1:  

Table 1. CHF RE-ADMISSION DATA EXTRACTION SHEET
 
MEDICAL RECORD NUMBER DURATION OF HOSPITAL STAY 
AGE
SEX SMOKING CESATION GIVEN Y/N 
BMI 
PAST MEDICAL HISTORY:
DM: HTN:CAD: CVA:CKD:PVD: 
MEDICATIONS:
PREADMISSION MEDICATIONS
SMOKING : Yes / No 
 LABS: Creatinine: BMP: Cardiac 
enzymes 
2D ECHO: EF 




DISCHARGE PLANNING AT 
DISCHARGE 

















Table 2. ABBREVIATIONS 
ABBREVIATIONS MEANING
ACEI Angiotensin converting enzyme inhibitor 
AMI Acute Myocardial infarction
ARB Aldosterone Receptor blocker 
BMI Body Mass Index 
BNP Brain Naturetic Peptide 
CAD Coronary Artery Disease 
CKD Chronic Kidney disease 


































Performance measures for Left ventricular function
Performance 
Measure 













Heart failure patients 
with documentation in 
the hospital record that 
left ventricular systolic 
(LVS) function was 
evaluated before arrival,
during hospitalization,
or was planned for after 
discharge
Documentation that left 
ventricular systolic function 
was evaluated before arrival,
during hospitalization, or
was planned for after 
discharge. Exclusions 
include patients with reasons 
documented by a physician,
nurse practitioner or 
physician assistant for no 
LVS assessment.  
Numerator: Heart 
failure patients with
documentation in the 
hospital record that 
LVS was evaluated 
before arrival, during
hospitalization, or is 
planned for after 
discharge
Denominator: Heart 
failure patients age 18
and older
 








   
  















   
   





Performance measure for ACEI 
Performance Measure Measure Description Criterion Met or Acceptable Alternative 
ACE Inhibitor or Angiotensin Heart failure patients 
with left ventricular 
Documentation that an ACE inhibitor or an
ARB was prescribed at discharge in patients 
Receptor Blocker (ARB) for systolic dysfunction with LVSD who were not participating in an
Left Ventricular Systolic 
(LVSD) and without
both Angiotensin 
ACE inhibitor alternative clinical trial at the 
time of discharge and where there is no






were prescribed an ACE 
inhibitor or an ARB at
hospital discharge
documentation of one or more of the
following potential contraindication/reason
for not prescribing an ACE inhibitor or an
ARB at discharge:
• ACE inhibitor allergy and ARB 
allergy  
• Moderate or severe aortic stenosis 
• Other reasons documented by a 
physician, nurse practitioner, or physician
assistant for not prescribing an ACE 
inhibitor and not prescribing an ARB at 
discharge
LVSD is defined as documentation of a left
ventricular ejection fraction (LVEF) less





































Performance measure for Discharge instructions 




Discharge Instructions Heart failure patients 
discharged home with
written instructions or 
educational material 
given to patient or care 
giver at discharge or
during the hospital stay
addressing all of the 
following: activity 




to do if symptoms
worsen
Documentation that
heart failure patients 
discharged to home, 
home care or home IV 
therapy, or their care
givers were given
written discharge 
instructions or other 
educational materials 
addressing all of the 
following: activity 













material addressing all 
of the following: 
activity level, diet, 
discharge medications,
follow-up appointment, 
weight monitoring, and 
what to do if symptoms
worsen Denominator: 
Heart failure patients 
age 18 and older 
discharged home 
 

































patients with a 
history of smoking




hospital stay  
Documentation that for heart
failure patients who are 
smokers (defined as someone 
who has smoked any time
during the year prior to 
hospital arrival), smoking
cessation advice or counseling 
was provided during the 
hospital stay  
Numerator: Heart failure 
patients (cigarette smokers) 
who receive smoking cessation 
advice or counseling during the 
hospital stay Denominator:
Heart failure patients age 18
and older with a history of
smoking cigarettes anytime 
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identified. The following items are exempt from review: 
o Protocol Version 1.1 (dated 6/22/2009) 
o Data Collection Tool (dated 6/4/2009) 
Your study has been granted a waiver from the requirement to secure 
authorization for the use of PHI.  
Should you make any changes to the procedures or project, please submit the 
revisions to the KHN IRB for review and determination prior to 
implementation. 
Upon completion of your project, please complete and submit a final report in 
addition to any resulting publications or reports.
You are free to conduct your study without continuing reviews by Kettering 
Health Network (KHN) IRB. 
Thank you for keeping the Board informed of your activities. If you have any 
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questions or need further information, please contact Gail Young ((937) 395-8309; 
fax (937) 395-8185; email: Gail.Young@khnetwork.org). 
Sincerely, 

Douglas Lehrer, M.D. 

Vice Chairperson, Institutional Review Board 

Enclosure: Application for Waiver of Authorization or Altered Authorization 

Under the HIPAA Privacy Rule (dated 6/4/2009) 

cc: IRB Files, Innovation Center 
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Institutional Review Board 
RESEARCH PROTOCOL  

TO: Kettering Health Network Institutional Review Board 
FROM: Principal Investigator: Sula Mazimba, M.D. 
Phone Number / Fax Number: 937-901-0215 
Mail Address: 33 W Rahn Rd, Suite 102 
Kettering, Ohio 45429 
Email Address:  sulamazi@yahoo.com 
DATE: 6/22/09 
STUDY TITLE: Impact of Congestive Heart Failure Discharge Planning on Congestive Heart 
Failure Re-Admission Rates
VERSION # 1.1 
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In this study, we hypothesize that the addition of the Congestive Heart Failure (CHF) 
discharge planning team has improved the rate of CHF readmission in the hospital.  Via 
retrospective chart review, we will review the rate of readmission before and the rate of
readmission after the introduction of the discharge planning for CHF. 
Purpose 
The purpose of this study is to assess the impact of discharge planning on the readmission 
rates for CHF and to assess compliance to recommended medications for CHF treatment. 
Background and Significance 
CHF is the most common inpatient diagnosis in the USA. It contributes to about 35 
billion dollars every year in health care costs. The bulk of the cost is due to readmission 
of patients. Discharge planning has been shown to improve patient adherence to 
discharge medications and compliance, and this may have an impact on re-admissions. 
The CHF discharge planning team was initiated in KMC in October 2006.This study aims
to evaluate the impact of this program to preventing readmissions in the hospital. 
Human Subject Population 
Method of Subject Identification and Recruitment 
All patients between the ages of 18-89 presenting to Kettering Medical Center with a 
CHF diagnosis between January 1, 1999 and December 4, 2008 will be reviewed in a 
retrospective fashion. Records will be sourced by ICD code 428.0.  Patient charts 
will be identified by assigning a number to the patient only if they meet the inclusion 
criteria. Only deidentified data will be used in this study. 
Gender of Subjects
Number of Subjects 
Up to 2000 subjects may be enrolled at KHN.
Age Range of Participants 





















o	 Patients between the ages of 18 and 89 
o	 Patients readmitted to Kettering Medical Center between 1999 and June 4,
2009 with a diagnosis of CHF 
Exclusion Criteria
○	 Patients under the age of 18 and over the age of 89 are excluded due to 
privacy concerns
○	 No readmission for CHF to KMC      
Vulnerable Subjects 
N/A
Research Design and Methods 
All patients between the ages 18-89 presenting to Kettering Medical Center between 
January 1, 1999 and December 4, 2008 will be reviewed in retrospective fashion as 
described above in the “Method of Subject Identification and Recruitment”. Only data 
existing in the medical record on or before June 4, 2009 will be reviewed.  Only those 
who fit our inclusion criteria will be considered.  We will review the chart to record the 
following information: age, sex, BMI, past medical history of HTN, DM, CAD, CVA, 
CKD, PVD, Smoking, Labs like blood sugar, creatinine, cardiac enzymes, BNP, 2D Echo 
EF, stress test, catheterization, duration of hospital stay, preadmission and discharge 
medications, number of readmissions in 6 months as well as 6 months follow up (AMI, 
CVA, and death). The aim of the study is to look at the rate of readmissions in the 
patients with CHF before and after the implementation of discharge planning.      
Surveys / Interviews / Questionnaires 
No patient surveys, interviews, or questionnaires will need to be completed for this study. 
Risks / Discomforts / Benefits
Risks: There is little-to-no risk associated with this retrospective study.  The data 
collection and storage processes will be protected as indicated by HIPAA guidelines.  
The recruitment process will be limited to diagnosis code and no individual consent will 
be necessary.  No form of deception will be used in this study.   
Benefits: The potential benefit of this study will be to help understand the factors 
influencing readmissions in patients with CHF and would eventually help us know if 
implementation of proper discharge planning can reduce the rate of readmissions in them 
Data Analysis and Data Monitoring
No ongoing data monitoring will occur as this is a retrospective study.  All data will be
analyzed by the Principal Investigator. 
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Data Storage and Confidentiality
All data will be stored on a password protected computer accessible only to study 
personnel. Data collected will be void of any identifying characteristics to prevent 
linking data to patients. When the data collection and study analysis is completed, all 
data will be permanently deleted.     
Estimated Period of Time to Complete the Study 
The estimated time to complete this study will be 12 months to allow time for data 
collection and analysis. 
Informed Consent
Subjects’ written, signed consent will be obtained. No 
Waiver of a signed consent is requested. No 
Waiver or alteration of consent is requested. Yes
Justifications for the request to waive signed consent are listed as follows: 
 The research involves no more than minimal risk to subjects as review of 
medical records is for limited information. 
 Subjects’ rights and welfare will not be affected by the waiver because the 
subjects are not being deprived of any clinical care in this retrospective 
review.
 The research could not practicably be conducted without the waiver as it is 
not feasible to locate approximately 2000 subjects to obtain consent what 
would not affect care they have already received 
 Subjects will not be provided with additional information because 
subjects’ care has already been completed for the study/condition.  The 





For this study we request a waiver of IRB fees. 
All other costs incurred for study supplies and time for data collection and analysis will 
be incurred by Principal Investigator. 
Attachments 
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Data Collection Tool 
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